Cargando…
The Role of Dyslipidemia in Atherogenesis in Peritoneal Dialysis Patients
BACKGROUND: To evaluate atherosclerotic changes in carotid arteries (CCA) in uremic patients before and after 18 months of continuous ambulatory peritoneal dialysis (CAPD) treatment, and to evaluate the impact of dyslipidemia and CAPD treatment on vascular remodeling. MATERIALS AND METHODS: We condu...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331554/ https://www.ncbi.nlm.nih.gov/pubmed/37434937 http://dx.doi.org/10.4103/abr.abr_1_23 |
_version_ | 1785070278982762496 |
---|---|
author | Rebić, Damir Begić, Edin Aziri, Buena Džubur, Alen Gogić, Ena Durak-Nalbantić, Azra Hamzić-Mehmedbašić, Aida Hasanspahić, Senad Granov, Nermir |
author_facet | Rebić, Damir Begić, Edin Aziri, Buena Džubur, Alen Gogić, Ena Durak-Nalbantić, Azra Hamzić-Mehmedbašić, Aida Hasanspahić, Senad Granov, Nermir |
author_sort | Rebić, Damir |
collection | PubMed |
description | BACKGROUND: To evaluate atherosclerotic changes in carotid arteries (CCA) in uremic patients before and after 18 months of continuous ambulatory peritoneal dialysis (CAPD) treatment, and to evaluate the impact of dyslipidemia and CAPD treatment on vascular remodeling. MATERIALS AND METHODS: We conducted a longitudinal, prospective study during 2020 and 2021 at the Clinic for Nephrology, Clinical Center University of Sarajevo. Patients with end-stage renal disease were included and were followed during 18 months of CAPD treatment. All patients were treated using commercially prepared biocompatible balanced dialysis solutions. Carotid intima-media thickness (IMT) and atherosclerotic plaques on the common carotid artery (CCA) were measured by echotomography. RESULTS: A total of 50 patients were included and were followed during 18 months of CAPD treatment. Lipid values in the serum of patients with CAPD were significantly lower after 18 months of CAPD treatment compared to the values before treatment, while the value of high-density lipoprotein (HDL) was significantly increased after 18 months of CAPD treatment. The values of IMT and the diameter of the CCA compared to the basal values were significantly lower (P < 0.001). CONCLUSION: We demonstrated significantly lower lipid values and higher HDL levels following CAPD treatment. Correct selection of the targeted pharmacological intervention can substantially impact the regression of vascular changes in patients on peritoneal dialysis. |
format | Online Article Text |
id | pubmed-10331554 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-103315542023-07-11 The Role of Dyslipidemia in Atherogenesis in Peritoneal Dialysis Patients Rebić, Damir Begić, Edin Aziri, Buena Džubur, Alen Gogić, Ena Durak-Nalbantić, Azra Hamzić-Mehmedbašić, Aida Hasanspahić, Senad Granov, Nermir Adv Biomed Res Original Article BACKGROUND: To evaluate atherosclerotic changes in carotid arteries (CCA) in uremic patients before and after 18 months of continuous ambulatory peritoneal dialysis (CAPD) treatment, and to evaluate the impact of dyslipidemia and CAPD treatment on vascular remodeling. MATERIALS AND METHODS: We conducted a longitudinal, prospective study during 2020 and 2021 at the Clinic for Nephrology, Clinical Center University of Sarajevo. Patients with end-stage renal disease were included and were followed during 18 months of CAPD treatment. All patients were treated using commercially prepared biocompatible balanced dialysis solutions. Carotid intima-media thickness (IMT) and atherosclerotic plaques on the common carotid artery (CCA) were measured by echotomography. RESULTS: A total of 50 patients were included and were followed during 18 months of CAPD treatment. Lipid values in the serum of patients with CAPD were significantly lower after 18 months of CAPD treatment compared to the values before treatment, while the value of high-density lipoprotein (HDL) was significantly increased after 18 months of CAPD treatment. The values of IMT and the diameter of the CCA compared to the basal values were significantly lower (P < 0.001). CONCLUSION: We demonstrated significantly lower lipid values and higher HDL levels following CAPD treatment. Correct selection of the targeted pharmacological intervention can substantially impact the regression of vascular changes in patients on peritoneal dialysis. Wolters Kluwer - Medknow 2023-05-19 /pmc/articles/PMC10331554/ /pubmed/37434937 http://dx.doi.org/10.4103/abr.abr_1_23 Text en Copyright: © 2023 Advanced Biomedical Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Rebić, Damir Begić, Edin Aziri, Buena Džubur, Alen Gogić, Ena Durak-Nalbantić, Azra Hamzić-Mehmedbašić, Aida Hasanspahić, Senad Granov, Nermir The Role of Dyslipidemia in Atherogenesis in Peritoneal Dialysis Patients |
title | The Role of Dyslipidemia in Atherogenesis in Peritoneal Dialysis Patients |
title_full | The Role of Dyslipidemia in Atherogenesis in Peritoneal Dialysis Patients |
title_fullStr | The Role of Dyslipidemia in Atherogenesis in Peritoneal Dialysis Patients |
title_full_unstemmed | The Role of Dyslipidemia in Atherogenesis in Peritoneal Dialysis Patients |
title_short | The Role of Dyslipidemia in Atherogenesis in Peritoneal Dialysis Patients |
title_sort | role of dyslipidemia in atherogenesis in peritoneal dialysis patients |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331554/ https://www.ncbi.nlm.nih.gov/pubmed/37434937 http://dx.doi.org/10.4103/abr.abr_1_23 |
work_keys_str_mv | AT rebicdamir theroleofdyslipidemiainatherogenesisinperitonealdialysispatients AT begicedin theroleofdyslipidemiainatherogenesisinperitonealdialysispatients AT aziribuena theroleofdyslipidemiainatherogenesisinperitonealdialysispatients AT dzuburalen theroleofdyslipidemiainatherogenesisinperitonealdialysispatients AT gogicena theroleofdyslipidemiainatherogenesisinperitonealdialysispatients AT duraknalbanticazra theroleofdyslipidemiainatherogenesisinperitonealdialysispatients AT hamzicmehmedbasicaida theroleofdyslipidemiainatherogenesisinperitonealdialysispatients AT hasanspahicsenad theroleofdyslipidemiainatherogenesisinperitonealdialysispatients AT granovnermir theroleofdyslipidemiainatherogenesisinperitonealdialysispatients AT rebicdamir roleofdyslipidemiainatherogenesisinperitonealdialysispatients AT begicedin roleofdyslipidemiainatherogenesisinperitonealdialysispatients AT aziribuena roleofdyslipidemiainatherogenesisinperitonealdialysispatients AT dzuburalen roleofdyslipidemiainatherogenesisinperitonealdialysispatients AT gogicena roleofdyslipidemiainatherogenesisinperitonealdialysispatients AT duraknalbanticazra roleofdyslipidemiainatherogenesisinperitonealdialysispatients AT hamzicmehmedbasicaida roleofdyslipidemiainatherogenesisinperitonealdialysispatients AT hasanspahicsenad roleofdyslipidemiainatherogenesisinperitonealdialysispatients AT granovnermir roleofdyslipidemiainatherogenesisinperitonealdialysispatients |